Sign in
Taking peoplePhase 1

A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of JWK008 in Patients With Mucopolysaccharidosis Type I

Key facts

Who runs it
West China Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 1
People taking part
6 people, planned
Started
22 Jul 2024
Expected to end
22 Jun 2029
Type of study
Interventional
Treatments tested
  • JWK008 Single intravenous infusion administration
Record updated
25 July 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Age≥ 18 years old
  • Diagnosis of MPS type I
  • Be able to understand the purpose, content, and possible risks of this clinical study, voluntarily participate in and sign the informed consent form
  • If the subject is female, her sexual partner must agree to use reliable contraception until 2 consecutive tests of vector sequence in the blood are negative; If the subject is male, the subject agrees to use reliable contraception until the semen sample is negative for 2 consecutive tests of the vector sequence
  • Magnetic resonance imaging (MRI) of the liver mass read by the radiologist is negative

Who cannot take part

  • Known to be unresponsive to ERT; or those who have been treated with intrathecal or intravenous laronidase and have serious adverse reactions, such as significant infusion-related reactions (IARs) or anaphylactic shock
  • Has contraindications for Corticosteroids
  • Current treatment with systemic (intravenous or oral) immunomodulators or steroid use (topical treatments such as asthma or eczema are allowed)
  • Previously received gene therapy or participated in interventional clinical studies within the past 12 weeks
  • The researcher believes that the subject is not suitable to participate in any concurrent clinically significant major diseases or other situations in the study
  • Have a history of chronic infections or other chronic diseases that researchers believe pose an unacceptable risk
  • Active severe infection or any other significant accompanying, uncontrolled medical condition(except for those caused by MPS I), including but not limited to kidney, liver, blood, gastrointestinal, endocrine, lung, nervous system, brain or mental illness, alcoholism, drug dependence, or any psychological disorder assessed by the researcher that may interfere with adherence to experimental protocol procedures or tolerance to JWK008 injection
  • History of active malignancy within the past 5 years (non-melanotic skin cancer or carcinoma in situ of the cervix is allowed)
  • Serum AAV5 neutralizing antibody titer is greater than 1:100
  • When filtering, one of the following situations exists:; Hepatitis B surface antigen (HBsAg) is positive, and the copy number of hepatitis B virus deoxyribonucleic acid (HBV-DNA) is>the upper limit of normal value (ULN); Hepatitis C virus antibody (HCV-Ab) is positive, and the copy number of hepatitis C virus ribonucleic acid (HCV-RNA) is>ULN; Receiving antiviral treatment for hepatitis B or C; The human immunodeficiency virus (HIV) test is positive and the CD4+T lymphocyte count is ≤ 200/mm3
  • Abnormal laboratory values considered clinically significant (ALT and/or AST >3× upper limit of normal (ULN), total bilirubin > 1.5× ULN, serum creatinine > 1.5× ULN, etc.)
  • Has contraindications for lumbar puncture
  • Circulating alpha-fetoprotein (AFP) is elevated or abnormal
  • Pregnant or lactating females
  • Unable or unwilling to comply with the visit and study evaluation schedule described in the clinical protocol

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is a single-center, single-arm, non-randomized, open-label, non controlled, dose-escalation, prospective clinical trial designed to assess the safety, tolerability, and preliminary efficacy of JWK008 injection in patients with MPS I.

The group in the trial

  • JWK008 injectionTreatment being tested

    The participants will be given 5.0×10\^12vg/kg or 2.0×10\^13vg/kg body weight of JWK008

    Treatment: JWK008 Single intravenous infusion administration

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of JWK008 Given by a Single Intravenous Infusion in Patients With Mucopolysaccharidosis Type I
Record updated
25 July 2024